Providing one-on-one support for our clients and partners as they navigate the long and winding road of model-informed drug discovery. Learn More
Simulations Plus and the University of Bath Awarded New FDA Grant (11/15/22) Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products (11/2/22) Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization…
Simulations Plus Releases GastroPlus® Version 9.8.3 (10/12/22) Simulations Plus Releases State-of-the-Art QSP Software for Interstitial Lung Disease (8/31/22) Simulations Plus Releases ADMET Predictor Version 10.4 (X.4) (5/26/22) Simulations Plus Releases MembranePlus 3.0 (3/10/22) Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1 (1/5/22)
Expanding access to high-quality medication for people in need Read More
In January 2020, Grace Fraczkiewicz celebrated her 20 years of service with Simulations Plus. Read About Her Journey
In August of 2018, Robert Fraczkiewicz celebrated his 20 years of service with Simulations Plus. Read About His Journey
Simulations Plus hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions. Read More
Simulations Plus announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share. Learn More
Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More
Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More
Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More
Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More
DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More
Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More
Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More
Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More
Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More
Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More
Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More
Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More